Anti ceacam1 antibodies and methods of using same

Abstract

A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974 is disclosed. Also provided are Antibodies and methods of using same.

What is claimed is: 
     
         1 . A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974. 
     
     
         2 . An isolated antibody or antibody fragment comprising an antigen recognition domain having the CDR sequences and orientation of the antibody produced from the hybridoma cell of  claim 1 . 
     
     
         3 . A method of immunomodulation, the method comprising contacting a CEACAM1-expressing lymphocyte with the antibody or antibody fragment of  claim 2 . 
     
     
         4 . A method of inhibiting migration or proliferation of a CEACAM1 expressing tumor cell, the method comprising contacting the CEACAM1 expressing tumor cell with the antibody or antibody fragment of  claim 2 , thereby inhibiting migration or proliferation of a CEACAM1 expressing tumor cell. 
     
     
         5 . A method of inhibiting CEACAM1 homotypic or heterotypic protein-protein interaction, the method comprising contacting a CEACAM1-expressing lymphocyte with the antibody or antibody fragment of  claim 2 , thereby inhibiting CEACAM1 homotypic or heterotypic protein-protein interaction. 
     
     
         6 . A pharmaceutical composition comprising as an active ingredient the antibody or antibody fragment of  claim 2 . 
     
     
         7 . A method for diagnosing a cancer characterized by over expression of CEACAM1 in a subject in need thereof, the method comprising: (i) contacting a control biological sample with an anti-CEACAM1 antibody or antibody fragment that recognizes CEACAM1 and comprises the same CDR sequences in the same orientation as the CDRs of the antibody produced from a hybridoma cell which has been deposited under ATCC Accession Number PTA-9974; (ii) contacting a biological sample suspected of having cancerous cells derived from the subject with the anti-CEACAM1 antibody or antibody fragment that recognizes CEACAM1; (iii) determining the levels of the immune-complexes formed in (i) and (ii); and (iv) comparing these levels; wherein a significantly higher level of immune-complex formation in the biological sample from the subject compared to the control biological sample is indicative of cancer in said subject. 
     
     
         8 . The method of  claim 7 , wherein said level of said immune-complex is determined by detecting a detectable moiety attached to said antibody or antibody fragment. 
     
     
         9 . The method of  claim 7 , wherein the control biological sample is: (i) a control cell; or (ii) a control serum. 
     
     
         10 . The method of  claim 7 , wherein the control biological sample is obtained from said subject: (i) prior to disease initiation; or (ii) following at least one previous treatment. 
     
     
         11 . The method of  claim 7 , combined with an additional method of diagnosing cancer selected from the group consisting of an imaging step of said subject, a molecular test, a surgical biopsy step, and a combination thereof. 
     
     
         12 . The method of  claim 11 , wherein the imaging step is performed to assist biopsy acquisition from said subject. 
     
     
         13 . The method of  claim 11 , wherein the molecular test is for detection of an additional cancer-related marker in said biological sample. 
     
     
         14 . The method of  claim 11 , wherein the surgical biopsy is for obtaining a biological sample from said subject. 
     
     
         15 . A method for diagnosing the severity of a cancer characterized by over expression of CEACAM1 in a subject in need thereof, the method comprising: (i) contacting a control biological sample with an anti-CEACAM1 antibody or antibody fragment that recognizes CEACAM1 that comprises the same CDR sequences in the same orientation as the CDRs of the antibody produced from a hybridoma cell which has been deposited under ATCC Accession Number PTA-9974; (ii) contacting a biological sample suspected of having cancerous cells derived from the subject with the anti-CEACAM1 antibody or antibody fragment that recognizes CEACAM1; (iii) determining the levels of the immune-complexes formed in (i) and (ii); and (iv) comparing these levels; wherein a significantly higher level of immune-complex formation in the biological sample from the subject compared to the control biological sample is indicative of the severity of the cancer in said subject. 
     
     
         16 . A method of treating cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of the antibody or antibody fragment that recognizes CEACAM1 and comprises the same CDR sequences in the same orientation as the CDRs of the antibody produced from a hybridoma cell which has been deposited under ATCC Accession Number PTA-9974; and further administering to the subject lymphocytes. 
     
     
         17 . The method of  claim 16  wherein the antibody or antibody fragment is attached to a cytotoxic moiety. 
     
     
         18 . The method of  claim 17  wherein said cytotoxic moiety comprises a cytotoxin, a chemokine, a chemotherapy, a pro-apoptotic, an interferon, a radioactive moiety, or combinations thereof. 
     
     
         19 . The method of  claim 16  wherein the lymphocytes are CEACAM1-expressing lymphocytes. 
     
     
         20 . The method of  claim 19  wherein the CEACAM1-expressing lymphocytes are Tumor Infiltrating Lymphocyte or NK cells. 
     
     
         21 . The method of  claim 19  wherein the CEACAM1-expressing lymphocytes are cytotoxic T cells. 
     
     
         22 . The method of  claim 19  wherein the lymphocytes are administered to the subject prior to administration of the antibody or antibody fragment. 
     
     
         23 . The method of  claim 19  wherein the lymphocytes are administered to the subject concomitantly administration of the antibody or antibody fragment. 
     
     
         24 . The method of  claim 19  wherein the lymphocytes are administered to the subject following administration of the antibody or antibody fragment. 
     
     
         25 . The method of  claim 19  wherein the lymphocytes are obtained from the subject and treated by ex-vivo expansion methods. 
     
     
         26 . The method of  claim 19  wherein the subject is treated by other anti-cancer treatment prior to administration of the antibody or antibody fragment or prior to administration of the lymphocytes. 
     
     
         27 . The method of claim  32  wherein the other anti-cancer treatment is chemotherapy or radiation therapy. 
     
     
         28 . The method of  claim 16  wherein the cancer is selected from the group consisting of: melanoma, sarcoma, lung cancer, cancer of the thyroid, breast cancer, colon cancer, prostate cancer, hepatic cancer, bladder cancer, renal cancer, cervical cancer, pancreatic cancer, leukemia, lymphoma, myeloid cell related cancer, ovarian cancer, uterus cancer, biliary cancer or endometrial cancer. 
     
     
         29 . The method of  claim 16  wherein the cancer is melanoma.